Buerger’s Disease Market Projected to Witness Vigorous Expansion by 2023

 Market research future has a half cooked research report on global Buerger’s disease market. The global Buerger’s disease market is growing continuously and expected to grow at a CAGR of 3.1% from 2017 to 2023

Market Highlights

The global Buerger’s disease market has been evaluated as a steady market and it is expected to continue growing in the near future. Increasing incidence of Buerger’s disease is the major driver for this market. Introduction and increasing adoption of advanced diagnostic tools and new therapies are another important factor for the market growth.

The market for Buerger’s disease was around USD 309.3 million in 2016 and is expected to reach USD 383.0 million by 2023 which is a projected CAGR of 3.1%.

Taste the market data and market information presented through more than 52 market data tables and figures spread over 82 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Buerger’s Disease Diagnosis Market Research Report–Global Forecast to 2023.”

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/4015 

Major players in Buerger’s disease market:

There are plenty of large and small market players which operate in this market: FUJIFILM Holdings Corporation (Japan), General Electric Company (US), Koninklijke Philips N.V. (Netherlands), pluristem (Israel), Shimadzu Corporation (Japan), Siemens Healthcare GmbH (Germany), STEMPEUTICS RESEARCH PVT LTD (India) Toshiba Medical Corporation (Japan), t2cure GmbH (Germany), and others.

Regional Analysis:

Considering the global scenario of the Buerger’s disease market, there are four main regions, America, Europe, Asia Pacific, and Middle East & Africa.

America is the largest market for Buerger’s disease. The Americas mainly include North America and Latin America. North America is holding the largest market share in which US is dominating this market. Some major factors like advanced diagnostic and treatment facilities, funding for research, clinical trials and new drugs and therapy development, and rapid adoption of new therapies, are the driving forces for the growth for North America Buerger’s disease market. Average annual incidents of this disease is 12.6% in US. European region is the second important market, especially West European countries are dominating this region. Eastern European countries are also showing significant growth in this market. Asia Pacific market is witnessing rapid growth due to increasing incidence and awareness of the diseases, increasing spending and government initiative to increase awareness as well as to provide affordable healthcare. Due increasing number of smokers, the incidence rate is higher in Asia and Middle East as compare to the Americas and Europe. Talking about the market scenario of Middle East & Africa, this region is expected to grow significantly during the forecast period due to various factors such as increasing number of smokers, and changing healthcare practices. While lack of knowledge, limited access to the required healthcare facilities, availability of required products are inhibiting the growth of this market etc.

Segmentation:

Global Buerger’s disease market has been segmented on the basis of diagnosis which comprise of blood tests, The Allen's test, Angiogram, tissue biopsy, and others. Angiogram is further sub-segmented into CT scan (Computerized Tomography), MRI (Magnetic Resonance Imaging) Scan, X-rays, and others.

On the basis of treatments, the market has been segmented into smoking cessation, and other treatments. Other treatments is further sub-segmented into medications, intermittent compression of the arms and legs, spinal cord stimulation, surgery, amputation, therapeutic angiogenesis, and others. Medication includes medications to dilate blood vessels, medications to improve blood flow, medications to dissolve blood clots, and others.

On the basis of end user, it is segmented into hospital and clinics, medical research centers, academic institutes, and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/buergers-disease-market-4015 

Lancet Market to Witness Widespread Expansion During 2020 to 2024

 Market Research Future published a Cooked research report on “Global Lancet Market Research Report - Forecast till 2024”  – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2024 

Global Lancet Market – Overview

Globally, lancets are being utilized by patients who are affected by endocrine related complications, cardiovascular issues, and many others. Lancets are being used for diabetes/glucose test, tests in infants, heel-stick screening tests, as well as for scarred emergency patients or severely burned patients. The global lancet market is growing at an exponential rate and it is expected to grow at a CAGR of 11.3% during 2016 to 2022.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/2078 

The increasing prevalence of diabetes and growing incidence number of contagious and non-contagious diseases has been the major factor for influencing the growth of the market. Incidence of contagious diseases is increasing rapidly on a global level. According to the WHO, it has been calculated that, infectious diseases like plaque which is also known as black death has an estimated 50 million deaths in the 14th century, this infectious disease can be a serious disease if not treated, this disease has a case fatality ratio of around 30%-60%, as of 2013 there were 783 cases worldwide which includes 126 deaths.

The global lancet market appears to be oligopolistic owing to the presence of large players active in the regional market. The market is also characterized by a reasonable degree of brand loyalty where establishing a brand name is difficult for newcomers. However, the cost involved in manufacturing setup is low to medium which discreetly comfort the new entrants to enter in the market easily.  Developments in the medical device industry are made to simplify the diagnosis, prevention, and treatment of various diseases. One of such device is lancet, which is capturing a huge market share due to its application. Safety lancets and personal lancets being the two major types of the lancets are dominating the global lancet market.

Industry Updates

June, 2016: F. Hoffmann-La Roche AG received European approval of Avastin Drug in combination with Tarceva for cancer patients with a specific type advance lung cancer.

January, 2016: Catalent Inc., a company involved in biologics announced its research collaboration with Roche on Smartag(TM) technology. Catalent claims Roche will pay Catalent an up-front fee of $1 million. Roche to provide additional research funding during the initial phase of the collaboration between these two companies. 

October, 2015: BD announced the acquisition of GenCellBio systems, an Irish biotech company that has developed proprietary technologies that address key biological analysis protocols, for an undisclosed consideration. The acquisition is expected to improve the BD’s Next Generation Sequencing line of products. 

August, 2015: Roche Holding AG acquired GeneWEAVE to strengthen offerings in microbiology diagnostics. Roche will pay GeneWEAVE shareholdsers $190 million upfront and up to $235 million in contingent product related milestones.

March, 2015: BD completed the acquisition of CareFusion Corporation (CareFusion) for $12.2 billion. CareFusion will operate as a wholly-owned subsidiary of BD. The acquisition is intended to enhance the medication management and patient safety solutions provided by BD. 

March, 2015: BD announced the acquisition of CRISI Medical Systems, a medical technology company focused on providing safety and delivery of IV injectable medications. The acquisition will strengthen BD’s position in addressing preventable medication errors and improve care delivery efficiencies. 

Global Lancets Market – Regional Analysis

The oligopolistic nature of the market with North America at its prime holding the largest regional share. The factors contributing to this major share include the well-established healthcare infrastructure and the high income generating end users. As of now the medical device industry is majorly established in the U.S. and Europe. But trends are showing enormous growth opportunity in Asia, wherein China will play a prominent role in both usage and development of medical devices.

Moreover, in terms of volume; manufacturers from China are anticipated to capture a large portion of the market, companies such as Guangzhou IMPROVE MEDICAL Technology Co. Ltd, SteriLance Medical (Suzhou) Inc., and others are contributing to this major portion. These companies have established their manufacturing unit worldwide.

Global Lancets Market - Competitive Analysis

Many key players involved in this market are keen in introducing new advanced safety lancets for the treatment of various contagious diseases. HTL-STREFA S.A. accounted for major market share of global lancet market, with more than 35% of market share. The large share of the company is attributed to the high demand for safety lancet globally. Moreover, this company has a strong sales and distribution network and this company also provides after sales services and help which play a major role in the satisfaction of the customers. F. Hoffmann-La Roche AG accounts for approximately 22% which can be attributed to their product the ACCU-CHEK which is one of the safety lancets having high demand in the market.

The major players in the market which have global operations of the Lancet market, and are consistently working for the development of the following technology are F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Greiner Bio One International GmbH, Improve Medical Technology Co. Ltd, Terumo Medical Corporation, Bayer Cropscience Limited, HTL-STREFA S.A, Sarstedt AG & Co and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/lancet-market-2078

Anti-Fungal Agents Market Projected to Witness Vigorous Expansion by 2022

 

Market research future published a half-cooked research report on Middle East and Africa Anti-fungal agents market. The Middle East and Africa Anti-fungal agents market is expected to grow at a CAGR of 3.5% during the period 2016 to 2022.

Market Highlights

Anti-fungal agents are used in the treatment of infections caused by fungus. According to global action fund for fungal infection, globally, over 300 million people of all ages suffer from a serious fungal infection every year. The market drivers include rising prevalence of fungal infections, rising awareness, rise of immunity deficient population such as geriatrics, rise in exposure to infectious agents due to environmental factors such as pollution especially by particulates and agriculture residues and climatic conditions such as humidity and temperature, occupational hazards such as Jock itch, crowding etc. Growth of fungal infection due to off label use of broad spectrum antibiotics is a prime factor for the growing market for anti-fungal agents.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/2582 

The market restraints include rising resistance to anti-fungal agents, use of air filters and air conditioning, excellent spectrum and efficacy of Azole class of anti-fungal agents, loss of patents and genericitization etc. Competition by generics is exceptionally strong and generics account for roughly 50% of total sales for anti-fungal agents. The market penetration is very easy as there has been loss of patents of block buster drugs. Over the counter drugs are an important reasons for the growth of anti-fungal agents market.

The Middle East and Africa anti-fungal agents market is segmented into therapeutic indication which is further segmented into aspergillosis, dermatophytosis, candidiasis and others. On the basis of drug class the sub-segments are azoles, pyrimidines, echinocandins, polyenes, allylamines, and others. By route of administration the market is further divided into oral, local and others.

The market for Middle East and Africa anti-fungal agents is extremely fragmented with a number of small and big players. The market is also affected by substandard and counterfeit products especially in poorer regions of Africa with weak regulatory framework. Product development especially for resistant fungal infections has the highest potential among all the strategies.

Key Players:

The major participants of this market are: Novartis AG, Pfizer, Inc., Sanofi-Aventis, Merck & Co., Inc., Enzon Pharmaceuticals, Inc., Bayer AG, Astellas Pharma, Inc., GlaxoSmithKline plc, Abbott, Sigma-Aldrich and others

Middle East and Africa Anti-Fungal Agents Market:

The Middle East and Africa Anti-fungal drugs market has been evaluated as a growing market and it is expected that the market will grow at a moderate CAGR in future. The Middle East and Africa Anti-fungal agents market is expected to grow with CAGR of ~3.5% during the forecast period. The growth will be primary channeled by the need of unmet medical needs, rising incomes of the population and the high prevalence of fungal infection in Africa. Environmental factors such as high humidity and temperature along with the rich biodiversity of Africa will positively affect the market growth of anti-fungal agents.

Regional Analysis:

Depending on geographic region, anti-fungal agents market is segmented into following countries: UAE, Egypt, Saudi Arabia, Kuwait, Qatar and Oman. UAE is the largest market followed by Egypt. However the future market will be led by the poor developed parts of Africa due to large unmet needs and the seasonal climatic conditions of Africa. The eastern parts of Africa is expected to have greater market share as compared to the hot and dry western coast.

Segmentation:

Middle East and Africa anti-fungal agents market has been segmented on the basis of therapeutic indication which comprises into aspergillosis, dermatophytosis, candidiasis and others. On the basis of drug class; market is segmented into azoles, pyrimidines, echinocandins, polyenes, allylamines, and others. On the basis of route of administration; market is segmented into oral, local and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/mea-anti-fungal-agents-market-2582

 

Urinary Catheters Market Ready for a Record Breaking Growth by 2022

 

Market Highlights

Urinary catheters are used for emptying the bladder during surgical procedures or when the patient has no control of the bladder during some medical disorders and conditions such as spina bifida, multiple sclerosis (MS), stroke or spinal injury etc. The market driving factors for Middle East and Africa urinary catheters market are rising geriatric population, rising rate of self-catheterization etc. The market constraining factors are leakage associated with external type catheters, discomfort associated with the use of catheters, low healthcare expenditure in Middle East and Africa, low reimbursement policies of poor regions especially Africa, embarrassment and stigma associated with the use of urinary catheters etc. However catheter associated urinary tract infection (CAUTI) remain the prime constraining factor of the Middle East and Africa urinary catheters market.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/2538 

The Middle East and Africa urinary catheters market is segmented into product type which is further segmented into intermittent catheters, indwelling (foley) catheters, external catheters and others. On the basis of construction material the sub-segments are rubber, plastic, silicone, latex and others. By end user the market is further divided into hospitals, ambulatory and home use.

The market for Middle East and Africa urinary catheters is fragmented with a number of small and big players. The market is also affected by substandard products especially in poorer regions of Africa with weak regulatory framework. Product development has the highest potential among all the strategies as the use of urinary catheters is fraught with infection. Better quality antibacterial film coated catheters will drive the future growth of the market.

Middle East and Africa Urinary Catheters market:

The Middle East and Africa Urinary Catheters market has been evaluated as a growing market and it is expected that the market will touch high growth figures in future. The Middle East and Africa Urinary Catheters market is expected to grow with CAGR of ~6.9% during the forecast period. The growth will be primary channeled by the need of unmet medical needs and rising incomes of the population.

The major participants of this market are: Coloplast A/S, Werkomed Pty Ltd, DISA Vascular, Medloyd Healthcare, Terumo Europe NV, Teleflex, Medtronic and others.

Regional Analysis:

Depending on geographic region, Urinary catheters market is segmented into following countries: UAE, Egypt, Saudi Arabia, Kuwait, Qatar and Oman. UAE is the largest market followed by Egypt. However the future market will be led by the poor developed parts of Africa due to large unmet needs. 

Segmentation:

Middle East and Africa urinary catheters market has been segmented on the basis of product type which comprises intermittent catheters, indwelling (foley) catheters, external catheters and others. On the basis of construction material; market is segmented into rubber, plastic, silicone, latex and others. On the basis of end users; market is segmented hospitals, ambulatory and home.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/urinary-catheters-market-2538

 

Global Hepatitis C Drugs Market is Expected to Experience Immense Growth During 2020 – 2022

 

Overview:

Market Research Future (MRFR) has released a new report on the global hepatitis C treatment market. The report provides a complete overview of the market’s historical statistics and growth trajectory, in addition to elaborating on the market’s present statistics and providing detailed projections regarding the market’s likely growth trajectory over the forecast period from 2016 to 2022. The global hepatitis C drugs market is expected to exhibit a steady 3.3% CAGR over the forecast period, rising from a valuation of USD 18.7 billion in 2015 to USD 22.7 billion by 2022.

The slow CAGR of the global hepatitis C drugs market is due to the steady drop in the number of patients of hepatitis C in developed regions and the increasing prospects of the unorganized herbal medicine industry in emerging regions.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/2487 

Thanks to consistent healthcare advancement initiatives and awareness efforts, the prevalence of hepatitis C has fallen in developed countries over the years and could in fact dip into negatives over the coming years due to the widespread availability of medication and widespread awareness about the disease. The improving sanitation levels in developed countries have been vital for the drop in the prevalence of hepatitis C, as it has reduced the likelihood of the respective pathogens breeding in large amounts. The increasing awareness about hygiene and disease prevention in countries such as the U.S., Canada, the UK, France, and Germany is likely to further reduce the prevalence of hepatitis C over the coming years, restraining the growth of the hepatitis C drugs market in developed economies.

In emerging regions such as Asia Pacific, hepatitis C is considerably prevalent. However, the disease is often treated with herbal remedies, which are available more easily and much cheaper than conventional medicine. This is likely to be a major restraint for the hepatitis C drugs market over the forecast period.

Segmentation:

The global hepatitis C drugs market is segmented on the basis of drug class, medicine system, route of administration, end user, and region.

The global hepatitis C drugs market is segmented on the basis of drug class into anti-viral drugs, immuno-modulators, and others.

On the basis of medicine system, the global hepatitis C drugs market is segmented into allopathic medicine, alternative medicine, and others.

On the basis of route of administration, the hepatitis C drugs market is segmented into oral, injectable, and others. Oral administration held the dominant share in the global hepatitis C drugs market in 2015 and is likely to remain the leading revenue generator over the forecast period.

On the basis of end user, the market is segmented into hospitals and private.

Regional Analysis:

The global hepatitis C drugs market is segmented by region into the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The Americas is likely to retain the dominant share in the global hepatitis C drugs market over the forecast period, followed by Europe, due to the widespread availability of advanced medication in the region. Due to the drop in the prevalence of the disease, the hepatitis C drugs market in North America and Europe is likely to remain stable or even reduce in size over the forecast period.

The hepatitis C drugs market is likely to exhibit promising growth prospects in emerging regions such as China and India over the forecast period. The growing prevalence of the disease in these regions, allied to the growing awareness about the prevention and treatment of the disease, is likely to drive the hepatitis C drugs market over the forecast period. Growth of the healthcare sector in countries such as India, China, Japan, Korea, Indonesia, Malaysia, and Singapore is likely to be vital for the global hepatitis C drugs market over the forecast period.

Competitive Analysis:

Leading players in the global hepatitis C drugs market include Gilead Sciences Inc., Johnson & Johnson, GSK, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Novartis AG, Merck & Co. Inc., and AbbVie Inc.

Industry Updates:

In February 2019, Indiana’s federal court enabled Medicaid recipients to receive direct-acting antiviral medications sooner.

FOR MORE DETAILS – @ https://www.marketresearchfuture.com/reports/hepatitis-c-drugs-market-2487

 

Global Urinary Incontinence Market Expected to Grow with a healthy CAGR

 

Overview:

Market Research Future (MRFR) in their latest report made an effort in providing the upcoming market scenario of the global urinary incontinence market in a holistic way. The urinary incontinence market is predicted to achieve a moderate CAGR and scale an impressive valuation of USD 27,775.9 million during the forecast period (2017-2022). Urinary incontinence denotes an unintentional leakage of urine under extreme stress or due to any kind of pressure on the bladder. It happens mostly in women. Women during pregnancy can experience the problem. Women of age group 30-60 are more prone to experience this problem than others. This occurs when a person loses his or her control over the urinary sphincter or the control gets weakened. The chance of a person contracting urinary incontinence grows with age. MRFR in their report talked in detail about the urinary incontinence market growth and harped on segments with both volume-wise and value-wise analysis. Simultaneously, the research also focuses on the competitive landscape and factors that can improve the urinary incontinence market dynamics in the coming years.

Increasing the level of stress, changes in lifestyle, pregnancy, and other reasons can trigger urinary incontinence. The patients are mostly divided into four types; constant-or-near-constant dribbles and leaks, stress-related leakage, urge-related incontinence, and inability to control the bladder. The urinary incontinence market is all set to receive backings from growing awareness in both developing and developed regions, latest technologies, infrastructural development, and demand for minimally invasive or non-invasive surgeries can help in the growth of the urinary incontinence market.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/1097 

Segmentation:

MRFR, for a better analysis of the global urinary incontinence market, segments it by types and devices.

Based on types, the global urinary incontinence market can be segmented into urge incontinence, stress incontinence, overflow incontinence, functional incontinence, and others. The stress incontinence segment has the largest market share as of the report. The urge incontinence segment is also expecting much growth during the forecast period.

Based on devices, the urinary incontinence market comprises electrical stimulation devices, Foley catheters, antimicrobial Foley catheters, urethral bulking agents and others. Foley catheters are getting much traction and are expected to keep their growth the same during the forecast period. Urethral bulking agents can work well with patients who have serious issues with anesthetic agents and cannot have surgical procedures.

Regional Analysis:

MRFR, in their region-specific analysis of the urinary incontinence market, includes the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).

The Americas can be segmented into North America and South America. North America churns out the maximum revenue amount of the global urinary incontinence market. The regional market is amply backed by superior infrastructure, robust healthcare segment, reimbursement policies, and high investment from individuals regarding health. People in this region are quite aware of the problem and seek specialist help quite often which helps the market with expansion.

Europe and the APAC market are projected to grow with the fastest CAGR over the review period. Government’s in Europe are backing the healthcare sector with funds that are getting invested in research and development. In the APAC, the regional market is profiting from the presence of a huge population base where the upliftment of the healthcare sector is ensuring widespread awareness and easy access to treatments.

Competitive Landscape:

Notable players in the urinary incontinence market, as reported by MRFR, are NeoTract, Inc, Promedon, Cook Medical Inc., C.R. Bard Inc., Coloplast Corp, Boston Scientific Corporation, Ethicon US, LLC and others. Their influence on the market has great strategic relevance which has also spurred expansion in the market.

In 2018, Triple W, a company based out of San Diego, launched a wearable device called DFree. The device can predict the toilet timing and thereby, can stop accidents. This would give patients a heads up so that they can find a lavatory in time.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/urinary-incontinence-market-1097

 

Alzheimer’s Disease Market - Factors Driving Growth Post 2020

 

Global Alzheimer’s disease Diagnostic Market   - Overview

The global Alzheimer’s disease therapeutics and diagnostic market is growing at a sound pace; mainly due to the increasing prevalence of the disease making it one of the major drivers for the market. According to a recent study report published by the Market Research Future, the global Alzheimer’s disease diagnostic market is booming and expected to gain prominence over the forecast period. The market will demonstrate a spectacular growth by 2022, surpassing its previous growth records in terms of value with a sound CAGR during the anticipated period (2017 – 2022).

The major drivers will be the increasing per capita healthcare expenditure and growing geriatric population. With it the market for diagnostic test, including diagnostic molecules and assays will contribute significantly to the health and wellbeing of the patients.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/2149 

In 2017, according to the Alzheimer's Association, 5.5 million Americans lives with Alzheimer's dementia, and estimated 5.3 million are at 65 years old or above. Moreover, according to the National Institute of Health, the global geriatric population is expected to reach 1.6 billion by 2050 from 617 million in 2016. From the illustrated facts it is clear that the market will grow significantly in the presence of the need of diagnostics.

Global Alzheimer’s Disease Diagnostic Market - Competitive Analysis

Characterized by the presence of several well-established and small players, the global market of Alzheimer’s disease diagnostic appears to be highly competitive and fragmented. International players are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features such as product differentiation, product portfolios, quality, and pricing.  The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among players.

Well established players followed acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.

Eli Lilly and Company is one of the major players in the global Alzheimer’s disease diagnostic market.  The total revenue generated by the company in 2016 was reported to be approximately around 21.2 billion. Followed by such huge revenue the company invested 24.7% of its revenue on the research and development. Following such a trends from the past few years, Eli Lilly and Company became a global leader in the fight against Alzheimer’s disease and it is leading the market since last 30 years. Today, Eli Lilly and Company has molecules to treat and diagnose Alzheimer’s disease in various stages of clinical development, including seven investigational compounds to treat Alzheimer’s disease and two diagnostics to help better diagnose the disease condition. To enhance the product development and commercialization the company in Jan. 27, 2016 announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42.

Eli Lilly and Company. (U.S.), TauRx (Asia Pacific), Accera, Inc. (U.S.), Treventis Corporation. (U.S.), Neuro-Bio Ltd (Europe), CogRx (U.S.) are some of the prominent players at the forefront of competition in the Global Alzheimer’s disease diagnostic Market and are profiled in MRFR Analysis. 

Global Alzheimer’s disease Diagnostic Market - Regional Analysis

The global market is led by the Americas. Rising per capita healthcare expenditures, presence of global players like CogRx and Accera, Inc. along with a huge patient population drives the market growth within the region. In 2015, according to the Centres for Disease Control and Prevention, in the U.S. the total healthcare expenditure accounted for 17.8% of the total gross domestic product (GDP), which accounted for USD 3.2 trillion. Europe is the second largest market. Huge patient population, increasing government support the R&D fuels the market growth within the region. According to the Alzheimer's Society, the number of the patients suffering from dementia in the U.K is expected to reach over one million by 2025. Asia Pacific region consists of the developing economies like India & China making it to be the fastest growing region.  The Middle East & Africa region holds the least share, especially due to the African region. The Middle East region holds the market of this region due to huge healthcare expenditures.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/alzheimers-disease-diagnostic-market-2149